

A'
now abandoned which is a continuation-in-part of U.S. Serial No. 07/206,470 filed 14 June 1988
and now abandoned which is a continuation-in-part of U.S. Serial No. 07/200,383 filed
31 May 1988 and now abandoned. Also related is U.S. Serial No. 07/460,855, now patent
No. 5,114,923 which is a continuation-in-part of U.S. Serial No. 07/299,880 listed above.

Please amend the claims as follows:

Please cancel claims 1-31 and substitute the following claims:

SUB C1
32. Antibodies useful for immunoassays to detect a peptide which peptide comprises
human or canine brain natriuretic peptide.

A2
SUB B1
33. The antibodies of claim 32 wherein said peptide is human brain natriuretic peptide
of the formula:

R¹-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-R²

wherein R¹ is selected from the group consisting of:

(H);
Gly-;
Ser-Gly-;
Gly-Ser-Gly-;
Gln-Gly-Ser-Gly-;
Val-Gln-Gly-Ser-Gly-;
Met-Val-Gln-Gly-Ser-Gly-;
Lys-Met-Val-Gln-Gly-Ser-Gly-;
Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-;
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-; and
R³-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-

wherein R³ is the 101 amino acid sequence shown for human BNP in Figure 8 at
positions numbered 1-99 immediately upstream of the Ser residue to which R³ is bound, or a
C-terminal portion thereof; and

SUB B2
R² is OH, NH₂ or NR₂ wherein each R is independently H or lower alkyl (1-4C); or R² is selected from the group consisting of:

Lys;
Lys-Val;
Lys-Val-Leu;
Lys-Val-Leu-Arg;
Lys-Val-Leu-Arg-Arg; and
Lys-Val-Leu-Arg-Arg-His, or
the C-terminal amides thereof.

Ag cont'd
SUB B3
34. The antibodies of claim 33 wherein the peptide is of the formula:
Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His,
or a C-terminal amide thereof.

Ag cont'd
35. The antibodies of claim 33 wherein, in said human brain natriuretic peptide, R³ is H and R² is OH or NH₂.

Ag cont'd
36. The antibodies of claim 33 wherein, in said human brain natriuretic peptide, R¹ is H and R² is OH or NH₂.

SUB B4
37. The antibodies of claim 32 wherein said peptide is canine natriuretic peptide of the formula:

R¹-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R²
wherein R¹ is selected from the group consisting of:

(H);
Gly-;
Ser-Gly-;
Lys-Ser-Gly-;
His-Lys-Ser-Gly-;
Met-His-Lys-Ser-Gly-;

Met-Met-His-Lys-Ser-Gly-;
Lys-Met-Met-His-Lys-Ser-Gly-;
Pro-Lys-Met-Met-His-Lys-Ser-Gly-; and
R³-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-;

wherein R³ is the 100 amino acid sequence of the dog prepro sequence upstream of the Ser residue to which R³ is bound shown in Figure 8 herein or a C-terminal portion thereof;
R² is OH, NH₂, or NR₂ wherein each R is independently H or lower alkyl (1-4C) or R² is Asn;
Asn-Val;
Asn-Val-Leu;
Asn-Val-Leu-Arg;
Asn-Val-Leu-Arg-Lys; or
Asn-Val-Leu-Arg-Lys-Tyr;
or a C-terminal amide thereof.

38. The antibodies of claim 37 wherein said canine natriuretic peptide is Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-Ser-Pro-Lys-Met-Met-His-Lys-Ser-Gly-Asn-Val-Leu-Arg-Lys-Tyr;
or a C-terminal amide thereof.

39. The antibodies of claim 37 wherein the said canine natriuretic peptide R³ is H and R² is OH or NH₂.

40. The antibodies of claim 37 wherein the said canine natriuretic peptide R¹ is H and R² is OH or NH₂.

41. The antibodies of claim 32 which are monoclonal antibodies.

42. The antibodies of claim 32 which further comprise a label.